In-office

Intuniv patient kit draws DDMAC untitled letter

Intuniv patient kit draws DDMAC untitled letter

By

Patient materials for Shire's ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA's Division of Drug Marketing, Advertising and Communication.

Email Newsletters